Emergent Signs a Five-Year Manufacturing Services Agreement with Janssen for Ad26.COV2-S to Treat COVID-19

 Emergent Signs a Five-Year Manufacturing Services Agreement with Janssen for Ad26.COV2-S to Treat COVID-19

Shots:

  • Emergent will be responsible to provide large-scale drug substance for manufacturing Janssen’s Ad26.COV2-S for the first two years valued at ~$480M in 2021. Additionally, at the beginning of 2023 Emergent will provide capacity deployment model for supporting additional drug substance batches annually for three years
  • The manufacturing practices will be performed at Emergent’s Baltimore Bayview facility a designated Center for Innovation in Advanced Development and Manufacturing (CIADM) by the US Department of HHS targeted for developing large quantities of vaccines and treatments
  • Emergent’s facility has four independent suites to produce at clinical scale and move to the clinic also allows scaling up of large-scale manufacturing to up to 4000L. Additionally, it holds the capacity to produce millions of doses of vaccines annually

Click here to read full press release/ article | Ref: Emergent | Image: Behance

Shiwani Sharma

Shiwani Sharma was Senior Editor at PharmaShots. She has in-depth knowledge of the life sciences industry including the Pharma and Biotech sectors. Any articles written by her can be contacted at connect@pharmashots.com.

Related post